CSL to de­fend patent claims

Townsville Bulletin - - NEWS -

AUS­TRALIAN vac­cines and blood prod­ucts de­vel­oper CSL has said it will vig­or­ously fight a patent in­fringe­ment claim launched by US- based biotech Biover­a­tiv in re­la­tion to CSL’s haemophilia B drug, Idelvion.

Biover­a­tiv, which de­vel­ops treat­ments for haemophilia and other rare blood dis­or­ders, has filed com­plaints in the US Dis­trict Court for the Dis­trict of Delaware and with the In­ter­na­tional Trade Com­mis­sion.

Biover­a­tiv claims that Idelvion in­fringes three Biover­a­tiv patents. “CSL is highly con­fi­dent of its in­tel­lec­tual prop­erty po­si­tion for Idelvion, a prod­uct of over a decade of in­no­va­tive re­search by CSL Behring … and will vig­or­ously de­fend against the claim,” CSL said in a state­ment yes­ter­day.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.